METFORMIN FOR ATRIAL FIBRILLATION

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 770 participants.

Also called NCT05878535

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 770 participants (planned count) (from the registry)
Sponsor
Arab Contractors Medical Centre (from the registry)
Registry
  • NCT NCT05878535
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05878535. Randomized; no masking; primary purpose treatment. Start 2024-06-01 (anticipated); primary completion 2025-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
METFORMIN FOR ATRIAL FIBRILLATION
Acronym
MAFT
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo
Lead sponsor
Arab Contractors Medical Centre (class: other)

Record details

Record id
cardio:ct-nct05878535
Content hash
187991176ebb9552666433e241149cc82837c582bc2f2dae20232182f025d7f0